Highest-materiality recent filing
Three directors resign after D&O insurance lapse; $550K convertible note issued
Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO
CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.
Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025
Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.
Sigyn Therapeutics effects 1-for-40 reverse stock split; symbol gets 'D' suffix for 20 days
Reverse stock split effective January 30, 2024 at a 1-for-40 ratio.
Sigyn Therapeutics effects 1-for-40 reverse stock split effective Jan 31, 2024
Reverse stock split ratio of 1-for-40 effective 12:01 a.m. ET on January 31, 2024.
Sigyn Therapeutics reports conversion of $1.32M debentures into 7.3M shares
Holders converted $1,322,200 of Original Issue Discount Senior Convertible Debentures at $0.18/share.
Sigyn Therapeutics completes animal study for Sigyn Therapy; safe and well-tolerated in 8 subjects
Eight porcine subjects received up to six-hour treatments; no serious adverse events reported.
Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.
On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.
On January 11, 2025, our Board of Directors appointed Michael Ryan to our Board of Directors.
the Company removed Jeremy Ferrell from his position as CFO of the Company, effective immediately.
The Company has appointed Jerry DeCiccio to serve as the Chief Financial Officer of the Company, effective immediately.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March 9, 2022.
Max materiality 0.80 · Median 0.50 · Most common event other_material